文献速递妇科生殖医学

CCR5/CCR5配体诱导的髓源性抑制细胞与子宫内膜异位症进展相关

CCR5/CCR5 ligand-induced myeloid-derived suppressor cells are related to the progression of endometriosis.
PubMed 文献 · Reprod Biomed Online · 2019-05-24

病例对照研究纳入36例子宫内膜异位症患者和20例对照,比较血浆及腹腔液中CCR5配体水平与外周血、腹腔液中CCR5+髓源性抑制细胞(MDSC)的聚集情况,发现患者CCL3、CCL5及CCR5+MDSC升高,且CCR5+MDSC与腹腔液CCL5水平相关。

要点

  • 子宫内膜异位症患者血浆CCL3及腹腔液CCL3/CCL5水平高于子宫肌瘤组。
  • 患者血及腹腔液中CCR5+MDSC、CCR5+Mo-MDSC聚集增加。
  • 腹腔液CCR5+MDSC与CCL5水平呈正相关(r=0.6807,P<0.0001)。

核心结论

  • CCR5及其配体可能通过增强MDSC聚集驱动子宫内膜异位症进展,靶向CCR5+MDSC可能成为有前景的治疗方向。

研究设计与样本

  • 病例对照研究,纳入36例子宫内膜异位症患者和20例对照,所有受试者均接受腹腔镜检查。
  • 采用ELISA检测血浆和腹腔液中CCR5配体,采用流式细胞术检测外周血和腹腔液中CCR5+MDSC。

主要发现

  • 子宫内膜异位症患者血浆CCL3(P=0.046)及腹腔液CCL3/CCL5(P=0.042/0.036)水平显著高于子宫肌瘤组。
  • 晚期患者腹腔液CCL5浓度高于子宫肌瘤组。
  • 子宫内膜异位症患者外周血CCR5+Mo-MDSC聚集高于卵巢皮样囊肿组和子宫肌瘤组。
  • 子宫内膜异位症患者腹腔液CCR5+MDSC和CCR5+Mo-MDSC高于子宫肌瘤组。
  • 腹腔液CCR5+MDSC(r=0.6807;P<0.0001)和CCR5+Mo-MDSC(r=0.6893;P<0.0001)富集与CCL5产生增强相关。

临床怎么用

  • 原文结论认为靶向CCR5+MDSC可能为子宫内膜异位症患者提供有前景的治疗,未给出具体临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RESEARCH QUESTION: Immunological disorders have been reported to promote the progression of endometriosis. Several recent studies have shown that myeloid-derived suppressor cells (MDSC) drive the progression of endometriosis. The aim of this case-control study was to test whether CCR5 and its ligands drive MDSC accumulation and play a role in the progression of endometriosis. DESIGN: Thirty-six endometriosis patients and 20 controls were recruited. All subjects underwent laparoscopy. An ELISA kit was used to define CCR5 ligands in plasma and peritoneal fluid from endometriosis patients; flow cytometry was then used to characterize CCR5+MDSC in peripheral blood and peritoneal fluid. RESULTS: Data showed that endometriosis patients displayed a significantly higher production of plasma CCL3 (P = 0.046) and peritoneal fluid CCL3/5 (P = 0.042/0.036) compared with those from the uterine leiomyoma group. Furthermore, the concentrations of peritoneal fluid CCL5 were elevated in late stage patients compared with those from the uterine leiomyoma group. Accumulation of blood CCR5+Mo-MDSC was detected in endometriosis patients compared with those from both the ovarian dermoid cysts and uterine leiomyoma groups. Endometriosis patients also showed an elevation of CCR5+MDSC and CCR5+Mo-MDSC in peritoneal fluid samples compared with uterine leiomyoma samples. It was also found that enrichment of CCR5+MDSC (r = 0.6807; P < 0.0001) and CCR5+Mo-MDSC (r = 0.6893; P < 0.0001) were correlated with enhanced production of CCL5 in peritoneal fluid from endometriosis patients. CONCLUSIONS: This study showed that CCR5 and its ligands could drive the progression of endometriosis by enhancing the accumulation of MDSC. These findings might produce a promising treatment that targets CCR5+MDSC for endometriosis patients.

来源:Reprod Biomed Online,查看原文。版权归原作者所有。

引用

  1. Guo P, Bi K, Lu Z, et al. CCR5/CCR5 ligand-induced myeloid-derived suppressor cells are related to the progression of endometriosis. Reprod Biomed Online. 2019. PMID: 31427176. doi:10.1016/j.rbmo.2019.05.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。